Zacks Investment Research on MSN
Will CRMD's bearish 2026 view impact DefenCath's long-term adoption?
CorMedix CRMD has been riding on the success of its lead product, DefenCath (taurolidine plus heparin), which was approved by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results